Evidence map›Paper›PMID 41361704›Full record

ReviewNature reviews. Nephrology2026

The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.

Amanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, Karen Ballen, Laura Cosmai, Roberta Fenoglio, Matteo Floris, Lui G Forni, Douglas E Gladstone, Ilya G Glezerman and 27 more

Abstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026
    Review
  4. Renal toxicity during VEGF-pathway inhibition in cancer: a practical review of proteinuria, hypertension, and kidney-limited thrombotic microangiopathy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Amanda DeMauro RenaghanDivision of Nephrology, University of Virginia Health System, Charlottesville, VA, USA. ajd9y@uvahealth.org.ORCID http://orcid.org/0000-0003-4536-9891
Marlies OstermannDepartment of Intensive Care & Nephrology, Guy's & St Thomas' Hospital, London, UK.ORCID http://orcid.org/0000-0001-9500-9080
Claudio RoncoUniversity of Padova, Padova, Italy.
Karen BallenDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA, USA.
Laura CosmaiNephrology and Dialysis Unit, Onco-Nephrology Outpatient Clinic, ASST Fatebenefratelli Sacco, Milan, Italy.
Roberta FenoglioUniversity Center of Excellence in Nephrology, Rheumatology and Rare Diseases, Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Turin, Turin, Italy.
Matteo FlorisDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Lui G ForniSchool of Medicine, University of Surrey & Intensive Care Unit, Royal Surrey NHS Foundation Trust, Guildford, Surrey, UK.ORCID http://orcid.org/0000-0002-0617-5309
Douglas E GladstoneNorthwell Health, New Hyde Park, NY, USA.
Ilya G GlezermanMemorial Sloan Kettering Cancer Center, Renal Service, New York, NY, USA.ORCID http://orcid.org/0000-0002-2212-9097
Stuart L GoldsteinCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Shruti GuptaAdult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5747-2151
Sandra M HerrmannDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3700-4537
Edgar A JaimesMemorial Sloan Kettering Cancer Center, Renal Service, New York, NY, USA.ORCID http://orcid.org/0000-0002-5756-5120
Kenar D JhaveriNorthwell Health, Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Sabine KaramDivision of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-0989-0241
Abhijat KitchluDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Canada.ORCID http://orcid.org/0000-0002-4340-5046
Heather J LandauAdult Bone Marrow Transplant & Cellular Therapy Services, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Sheron LatchaMemorial Sloan Kettering Cancer Center, Renal Service, New York, NY, USA.
David E LeafDivision of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7875-090X
Paolo LentiniInternational Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.ORCID http://orcid.org/0000-0001-9706-1579
Jolanta MałyszkoDepartment of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Glen MarkowitzDepartment of Pathology & Cell Biology, Columbia University Medical Center, New York, NY, USA.
Naoka MurakamiDivision of Nephrology, Washington University in St. Louis, St. Louis, MO, USA.
Antonello PaniDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Mark A PerazellaSection of Nephrology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6994-2659
Arash RashidiDivision of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Dario RoccatelloUniversity Center of Excellence in Nephrology, Rheumatology and Rare Diseases, Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-4419-6813
Elad SharonDana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Ben SprangersDivision of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium.ORCID http://orcid.org/0000-0003-1314-9675
Vladimír TesařDepartment of Nephrology, General University Hospital, Charles University, Prague, Czech Republic.ORCID http://orcid.org/0000-0001-6982-0689
Verônica TorresServiço de Nefrologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-8211-018X
Rimda WanchooNorthwell Health, Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Andrew WhitmanDepartment of Pharmacy, University of Virginia Health System, Charlottesville, VA, USA.
Biruh T WorkenehUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diana Zepeda-OrozcoThe Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Mitchell H RosnerDivision of Nephrology, University of Virginia Health System, Charlottesville, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past few decades, advances in understanding of cancer biology have led to the development of highly effective conventional chemotherapies, targeted therapies that act on specific pathways that are critical to cancer growth, immune-based therapies, and cellular therapies such as haematopoietic cell transplantation and chimeric antigen receptor T cell therapy. However, the nephrotoxic effects of these therapies continue to pose substantial challenges, with many unanswered questions regarding the prevention, diagnosis and management of this nephrotoxicity. Further, a lack of consensus and precise guidance on kidney function estimation and drug dosing for patients with acute kidney disease or chronic kidney disease and for patients receiving kidney replacement therapy limits access to life-saving therapies and jeopardizes outcomes. In this Consensus Statement, we present guidance on the prevention, diagnosis and management of anticancer therapy nephrotoxicity for adult patients that was developed at the 34th Acute Disease Quality Initiative meeting, which convened an international panel of experts in nephrology, haematology, oncology, nephropathology, critical care, paediatric care and pharmacology. We also define a research agenda focused on preventing and mitigating anticancer therapy toxicity, maximizing early detection of nephrotoxicity and enabling optimal drug dosing in patients with kidney disease, with the goal of advancing cancer care and fulfilling the potential of these ground-breaking treatments.

Indexed as

Acute Kidney InjuryAntineoplastic AgentsNeoplasmsRenal Insufficiency, ChronicHumansAntineoplastic Agents

Identifiers

PMID41361704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.